Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Odontis was a London-based biotechnology company dedicated to the field of regenerative dentistry, specifically focusing on the creation of bioengineered teeth. A spin-out from King's College London, the company leveraged the research of Professor Paul Sharpe to develop a method for growing new teeth from a patient's own stem cells. The technology involved the assembly of mesenchymal and epithelial cells into a tooth primordium, which could then be implanted into the gum to develop into a natural tooth. Although the company attracted significant venture capital and grant funding, it ceased operations and was dissolved in 2011. The work of Odontis laid the groundwork for subsequent research into biological tooth replacement.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Odontis.